Category Archives: FDA Policy

OPDP Sends Third Enforcement Letter of the Year

The folks at the Office of Prescription Drug Promotion (OPDP) have been in the mood lately to make a point. You can tell because they recently issued the third regulatory action letter of the year. Many years ago this would … Continue reading

Posted in FDA Policy, Warning Letters | Comments Off on OPDP Sends Third Enforcement Letter of the Year

OPDP Takes Second Enforcement Action of the Year

This week FDA’s Office of Prescription Drug Promotion (OPDP) posted what was only the second enforcement letter of the year which was issued in May. Warning letters are issued by many parts of the FDA, but OPDP issues letters squarely … Continue reading

Posted in FDA Policy, Warning Letters | Comments Off on OPDP Takes Second Enforcement Action of the Year

Speaking of Communications – OPDP on the Move

Over the past few years, regulatory action letters from FDA’s Office of Prescription Drug Promotion (OPDP), while once plentiful, has been something of a rare occurrence. In response to questions on the matter, FDA was often vague. This week however, … Continue reading

Posted in FDA Policy, Warning Letters | 2 Comments

HHS Proposes Pricing in DTC

In May the Administration released a plan called “America’s Patients First” , a blueprint to lower drug prices and reduce out-of-pocket costs. One of the items contained in that blueprint was to have the manufacturers of medicines include the list … Continue reading

Posted in DTC Advertising, FDA Policy | Tagged , , , | Comments Off on HHS Proposes Pricing in DTC

Mid-Year Check on the Pace of New Drug Approvals at FDA

At the mid-year point, I usually do a check-in to see how we are doing on new drug approvals and how it compares to years gone by. I am quite tardy checking in on that front, so let’s get it … Continue reading

Posted in FDA Policy | Comments Off on Mid-Year Check on the Pace of New Drug Approvals at FDA